- Home
- DFP vs TBPH Comparison
DFP vs TBPH Comparison
Compare DFP & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DFP
- TBPH
- Stock Information
- Founded
- DFP 2013
- TBPH 2013
- Country
- DFP United States
- TBPH United States
- Employees
- DFP N/A
- TBPH N/A
- Industry
- DFP Investment Managers
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- DFP Finance
- TBPH Health Care
- Exchange
- DFP Nasdaq
- TBPH Nasdaq
- Market Cap
- DFP 418.8M
- TBPH 454.7M
- IPO Year
- DFP N/A
- TBPH N/A
- Fundamental
- Price
- DFP $20.27
- TBPH $9.30
- Analyst Decision
- DFP
- TBPH Buy
- Analyst Count
- DFP 0
- TBPH 4
- Target Price
- DFP N/A
- TBPH $13.75
- AVG Volume (30 Days)
- DFP 56.2K
- TBPH 291.7K
- Earning Date
- DFP 01-01-0001
- TBPH 02-26-2025
- Dividend Yield
- DFP 6.73%
- TBPH N/A
- EPS Growth
- DFP N/A
- TBPH N/A
- EPS
- DFP N/A
- TBPH N/A
- Revenue
- DFP N/A
- TBPH $64,381,000.00
- Revenue This Year
- DFP N/A
- TBPH $36.49
- Revenue Next Year
- DFP N/A
- TBPH $14.66
- P/E Ratio
- DFP N/A
- TBPH N/A
- Revenue Growth
- DFP N/A
- TBPH 12.12
- 52 Week Low
- DFP $15.45
- TBPH $7.44
- 52 Week High
- DFP $19.31
- TBPH $10.90
- Technical
- Relative Strength Index (RSI)
- DFP 38.84
- TBPH 48.16
- Support Level
- DFP $20.31
- TBPH $9.12
- Resistance Level
- DFP $20.50
- TBPH $9.91
- Average True Range (ATR)
- DFP 0.18
- TBPH 0.40
- MACD
- DFP -0.03
- TBPH 0.01
- Stochastic Oscillator
- DFP 2.04
- TBPH 35.82
About DFP Flaherty & Crumrine Dynamic Preferred and Income Fund Inc.
Flaherty & Crumrine Pref&Inc Allocation is a diversified, closed-end management investment company. Its investment objective is to seek total return, with an emphasis on high current income.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).